Tell me what is wrong with posting this on the Yahoo Finance Board for AVDL?
On March 1, 2023, Avadel Pharmaceuticals plc submitted an amendment to its New Drug Application to the U.S. Food and Drug Administration (“FDA”) requesting final approval for LUMRYZ for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy.
The submission follows the FDA submission by Jazz Pharmaceuticals of February 28, 2023, requesting delisting of U.S. Patent No. 8,731,963 from FDA’s Orange Book pursuant to the United States Court of Appeals for the Federal Court decision of February 24, 2023, affirming the previous ruling from the United States District Court for the District of Delaware, ordering such delisting.
Hu
shared this idea
-
Hu
commented
Fundamentally I don't see how I can use a finance conversation platform which doesn't allow me to post perfectly legitimate and timely messages about that stock!
-
Hu
commented
This got rejected 3 times despite removing the link. There is NOTHING wrong with this comment. It doesn't infringe other people's copyright and it is entirely on message.